Press release
Strong Growth Ahead: Graft Versus Host Disease (GVHD) Treatment Market Size To Grow At Arecord 7.5% Cagr By 2029
Graft Versus Host Disease (GVHD) Treatment
How Big Is the Graft Versus Host Disease (GVHD) Treatment Market Size Expected to Be by 2034?
The graft versus host disease (GVHD) treatment market size has seen strong growth in recent years. It will increase from $2.85 billion in 2024 to $3.07 billion in 2025, at a compound annual growth rate (CAGR) of 7.7%. Growth drivers include a rise in allogeneic transplantations, growing incidence of acute GVHD, increasing rates of hematopoietic stem cell treatments, and the growing demand for bone marrow transplants.
The graft-versus-host disease (GVHD) treatment market is expected to see strong growth, reaching $4.1 billion by 2029 at a CAGR of 7.5%. Growth factors include the rising number of allogeneic transplants, increasing acute GVHD cases, more hematopoietic stem cell treatments, higher bone marrow transplant demand, the rising global prevalence of GVHD, and advancements in technology. Major trends include partnerships, investment, product approvals, and tailored treatments.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15579
What Are the Emerging Segments Within the Graft Versus Host Disease (GVHD) Treatment Market?
The graft versus host disease (GVHD) treatment market covered in this report is segmented -
1) By Product Type: Corticosteroids, Monoclonal Antibodies, Immunosuppressants, Others
2) By Disease Type: Acute GvHD, Prophylaxis GvHD, Chronic GvHD
3) By End User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Budesonide
2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab), Anti-il-2r? Monoclonal Antibodies ( Basiliximab), Anti-cd52 Monoclonal Antibodies (Alemtuzumab), Anti-il-6 Monoclonal Antibodies (Tocilizumab), Anti-Cd20 Monoclonal Antibodies (Rituximab)
3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus), Methotrexate, Mycophenolate Mofetil, Azathioprine, Sirolimus (Rapamycin), Cyclophosphamide
4) By Others: Mesenchymal Stem Cells (Mscs), Jak Inhibitors ( Ruxolitinib), Extracorporeal Photopheresis (Ecp), Thalidomide, Antithymocyte Globulin (Atg), Colony-Stimulating Factors (Filgrastim)
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp
What Long-Term Drivers Are Shaping Graft Versus Host Disease (GVHD) Treatment Market Trends?
Rising cases of blood-related disorders are driving the graft-versus-host disease (GVHD) treatment market. Blood disorders like leukemia and lymphoma are increasing due to unhealthy lifestyles, environmental exposure, and genetics. GVHD treatments, initially developed for transplant complications, now have broader application for immune modulation. According to the Leukemia & Lymphoma Society, blood cancers were expected to cause 57,380 deaths in the U.S. in 2023-equivalent to one death every 10 minutes. This growing burden is propelling the GVHD treatment market.
Who Are the Top Competitors in Key Graft Versus Host Disease (GVHD) Treatment Market Segments?
Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix
What Trends Are Expected to Dominate the Graft Versus Host Disease (GVHD) Treatment Market in the Next 5 Years?
Leading enterprises operating in the graft vs host disease (GVHD) treatment market are focusing on the advancement and approval of new drugs to gain a competitive advantage. Gaining product approvals is vital to ensure that medical products adhere to necessary safety, efficacy, and quality standards prior to patient availability. For instance, Incyte Corporation, an American healthcare firm, received approval from the US-based Food and Drug Administration in March 2023 for its newly developed ruxolitinib extended-release (XR) tablets. This JAK1/JAK2 inhibitor was designed for daily use and intended to treat certain types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/graft-versus-host-disease-gvhd-treatment-global-market-report
Which Regions Are Becoming Hubs for Graft Versus Host Disease (GVHD) Treatment Market Innovation?
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Graft Versus Host Disease (GVHD) Treatment Market?
2. What is the CAGR expected in the Graft Versus Host Disease (GVHD) Treatment Market?
3. What Are the Key Innovations Transforming the Graft Versus Host Disease (GVHD) Treatment Industry?
4. Which Region Is Leading the Graft Versus Host Disease (GVHD) Treatment Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Strong Growth Ahead: Graft Versus Host Disease (GVHD) Treatment Market Size To Grow At Arecord 7.5% Cagr By 2029 here
News-ID: 4039549 • Views: …
More Releases from The Business Research Company
Emerging Markets And Increasing Disposable Income Fueling Diamond Market Growth: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Diamond Market Through 2025?
In the past few years, there has been a stable expansion in the diamond market size. The prediction is it will increase from $1.33 billion in 2024 to $1.39 billion in 2025, boasting a compound annual growth rate…
2025-2034 Nonmetallic Minerals Mining Support Activities Market Outlook: Key Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Nonmetallic Minerals Mining Support Activities Industry Market Size Be by 2025?
In the past few years, there has been a robust expansion in the size of the nonmetallic minerals mining support activities market. It is projected to escalate from $34.04 billion in 2024 to $36.55 billion…
Professional Street Sweeper Industry Outlook 2025-2029: Market Set to Cross $3.1 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Professional Street Sweeper Market Size By 2025?
The market size of professional street sweepers has seen significant expansion in the past few years. The market, predicted to rise from $2.37 billion in 2024 to $2.5 billion in 2025, boasts a compound annual growth rate (CAGR)…
Key Trends Reshaping the Industrial Wet Dust Collector Market: Advanced Filtrati …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Industrial Wet Dust Collector Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a robust growth in the size of the industrial wet dust collector market. It is expected to swell from $1.89 billion in 2024 to $2 billion by 2025, showing a…
More Releases for GVHD
Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100…
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The…
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain…
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.
Graft-versus-host disease (GVHD) is a complication that can occur after…
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a…
